Prevalence of the metabolic syndrome in German women with polycystic ovary syndrome.

The aim of our study was to evaluate the prevalence of the metabolic syndrome (MBS) according to the current International Diabetes Federation definition in German PCOS women. Four hundred and eleven PCOS patients (age 28+/-6.3 years) and 82 controls (age 28+/-7.5 years) were evaluated for anthropometric and metabolic parameters by physical examination, blood testing and a personal interview including family history. A subgroup analysis of controls with BMI-matched PCOS women (BMI 22.9+/-2.8 kg/m (2)) was performed to detect PCOS specific differences in metabolic variables between the groups. The MBS was found in 33.8% of PCOS women compared to 7.3% in the control group. Parameters of insulin resistance, lipid-and glucose metabolism, mean values of all criteria of the MBS as well as the prevalence of the MBS were significantly different between the entire PCOS cohort and controls, but did not differ between BMI-matched PCOS women and controls. In addition, the prevalence of the MBS increased with age. Moreover, in PCOS women an increase in BMI and insulin resistance was accompanied by a further significant increase in the severity of clinical and biochemical hyperandrogenism. In PCOS women, while one out of three PCOS women had the MBS, the presence of metabolic abnormalities did not appear to be associated with PCOS per se, but rather correlated with age and the degree of obesity.

[1]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[2]  D. Cibula,et al.  Metabolic syndrome in young Czech women with polycystic ovary syndrome. , 2005, Human reproduction.

[3]  A. Dokras,et al.  Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome , 2005, Obstetrics and gynecology.

[4]  J. Nestler,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(4):1929–1935 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1045 Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycysti , 2022 .

[5]  D. Ehrmann,et al.  Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  Won-Young Lee,et al.  Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III. , 2005, Diabetes research and clinical practice.

[7]  Ricardo Azziz,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6):2745–2749 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-032046 The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected , 2022 .

[8]  O. Zinder,et al.  Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.

[9]  B. Choi,et al.  Prevalence of the Metabolic Syndrome and Its Association with Cardiovascular Diseases in Korea , 2004 .

[10]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[11]  N. Goldenberg,et al.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. , 2003, Metabolism: clinical and experimental.

[12]  R. Jennrich,et al.  Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome. , 2003, Metabolism: clinical and experimental.

[13]  Richard S Legro,et al.  Polycystic ovary syndrome and cardiovascular disease: a premature association? , 2003, Endocrine reviews.

[14]  R. Cífková,et al.  Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. , 2003, Human reproduction.

[15]  A. Balen,et al.  Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? , 2002, Clinical endocrinology.

[16]  R. Wild.  Long-term health consequences of PCOS. , 2002, Human reproduction update.

[17]  A. Kunselman,et al.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. , 2001, The American journal of medicine.

[18]  P. Giral,et al.  Smaller LDL particle size in women with polycystic ovary syndrome compared to controls , 2001, Clinical endocrinology.

[19]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[20]  P. Bezemer,et al.  Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. , 2001, Human reproduction.

[21]  R. Walker,et al.  Diagnosing insulin resistance in the general population. , 2001, Diabetes care.

[22]  K. Masuo,et al.  Familial Obesity, Sympathetic Activation and Blood Pressure Level , 2001, Blood pressure.

[23]  E. Fracassi,et al.  Waist circumference and abdominal sagittal diameter as surrogates of body fat distribution in the elderly: their relation with cardiovascular risk factors , 2000, International Journal of Obesity.

[24]  I. Vauhkonen,et al.  Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome , 2000 .

[25]  P. McKeigue,et al.  Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study , 2000, Clinical endocrinology.

[26]  L. Berglund,et al.  Sagittal abdominal diameter compared with other anthropometric measurements in relation to cardiovascular risk , 2000, International Journal of Obesity.

[27]  M. Cavaghan,et al.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. , 1999, Diabetes care.

[28]  M. Trevisan,et al.  Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. , 1998, American journal of epidemiology.

[29]  L. Kuller,et al.  Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. , 1998, Journal of clinical epidemiology.

[30]  D. Johnston,et al.  Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries , 1996, Clinical endocrinology.

[31]  C. Berne,et al.  Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? , 1996, Human reproduction.

[32]  H. Yki-Järvinen,et al.  Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[33]  S. Johansson,et al.  Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women , 1992, Acta obstetricia et gynecologica Scandinavica.

[34]  J. Clore,et al.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[35]  G A Colditz,et al.  A meta-analysis of physical activity in the prevention of coronary heart disease. , 1990, American journal of epidemiology.

[36]  K. Segal,et al.  Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.

[37]  A. Kissebah,et al.  The relationship of insulin to sex hormone-binding globulin: role of adiposity. , 1989, Fertility and sterility.

[38]  P. Coulson,et al.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. , 1985, The Journal of clinical endocrinology and metabolism.